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Abstract. Previous reports have demonstrated that the combination of 9-tetrahydrocannabinol (9-THC) and cannabidiol
(CBD) botanical extracts, which are the components of an already approved cannabis-based medicine, reduce the Alzheimer-
like phenotype of APP/PS1 transgenic mice when chronically administered during the early symptomatic stage. Here, we
provide evidence that such natural cannabinoids are still effective in reducing memory impairment in APP/PS1 mice at
advanced stages of the disease but are not effective in modifying the A processing or in reducing the glial reactivity associated
with aberrant A deposition as occurs when administered at early stages of the disease. The present study also demonstrates
that natural cannabinoids do not affect cognitive impairment associated with healthy aging in wild-type mice. The positive
effects induced by 9-THC and CBD in aged APP/PS1 mice are associated with reduced GluR2/3 and increased levels of
GABA-A Rα1 in cannabinoid-treated animals when compared with animals treated with vehicle alone.
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INTRODUCTION
Dementia is a general term referring to a progres-
sive decline in cognitive abilities occurring usually
in the elderly due to a variety of causes. Among
the symptoms, memory loss, language impairment,
attention deficiencies, and difficulty in reasoning
and judgment are the most prominent. Etiologies of
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dementia may be divided into two broad categories:
(i) degenerative, reflecting pathological processes
which are intrinsic to the central nervous system
and usually involve aberrant protein processing, and
(ii) non-degenerative, which include acquired or
secondary dementias linked to vascular, endocrine,
traumatic, and other primary central and systemic dis-
eases. Alzheimer’s disease (AD) is the most common
type of dementia, accounting for 60 to 80% of cases,
and is characterized by the presence in the brain of
extracellular deposits of amyloid- (A), a peptide
derived from the aberrant processing of the trans-
membrane amyloid- protein precursor (APP),
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and intracellular neurofibrillary tangles composed of
hyperphosphorylated microtubule-associated protein
tau. AD is also associated with neuroinflammation
and oxidative stress, two pathological processes that
exacerbate neurodegeneration during AD progres-
sion [1, 2].
Recent studies have demonstrated the therapeutic
effects of several compounds acting on the endo-
cannabinoid system in neurodegenerative diseases
such as AD [3–6]. The endocannabinoid system is
a complex network of cellular receptors and sig-
naling molecules [7] highly expressed in brain and
targeted by cannabis derivatives which, when acti-
vated, provides neuroprotection by reducing neuronal
damage, neuroinflammation, and oxidative stress,
as well as promoting intrinsic repair mechanisms
[3]. Thus, chronic stimulation with selective syn-
thetic agonists of CB1 and CB2 receptors, the most
well-known cannabinoid receptors, reduces cognitive
impairment and brain alterations associated with A
production, in at least three different animal mod-
els of AD [8–11]. Moreover, the combination of
9-tetrahydrocannabinol (9-THC) and cannabid-
iol (CBD), two phytocannabinoids produced by the
plant Cannabis sativa, reduces the pathological phe-
notype in mouse models of AD and tauopathy when
administered at early stages of the disease [12, 13].
These natural compounds are the two main compo-
nents of Sativex®, which is a well-tolerated medicine
prescribed for the treatment of spasticity associated
with multiple sclerosis.
The aim of the present study was to broaden our
knowledge about the potential beneficial effect of the
9-THC and CBD combination in reducing demen-
tia symptoms at advanced stages of the disease. The
present study was designed to evaluate the effect
of this cannabis-based medicine administered in old
APP/PS1 mice and in aged wild-type littermates.
Our results may contribute to increased understand-
ing of the possible use of the 9-THC and CBD
combination in demented patients.
MATERIALS AND METHODS
Animals
The experiments were carried out in male
APP/PS1 mice and wild-type-like (WT) littermates
aged 12 months at the onset of the study and in male
WT mice aged 3 months (non-aged controls) with
a C57Bl6J genetic background. The generation of
mice expressing the human mutated APPswe and
PS1dE9 has been described elsewhere [14]. All the
animals used in this study derived from 7 breeder
pairs. Animals were maintained under standard ani-
mal housing conditions (static isolation caging, 3-4
animals per cage) in a 12-h dark-light cycle with
free access to food and water. Mice were randomly
assigned to treatment groups and the experiments
were conducted under blind conditions. All animal
procedures were carried out following the guide-
lines of the European Communities Council Directive
2010/63/EU and with the approval of the local ethical
committee of the University of Barcelona.
Pharmacological treatment
9-THC-enriched botanical extract (containing
67.0% 9-THC, 0.8% CBD, 1.2% cannabigerol,
0.9% cannabichromene and 3.2% other phyto-
cannabinoids) and CBD-enriched botanical extract
(containing 62.7% CBD, 3.6% 9-THC, 1.4%
cannabigerol, 5.7% cannabichromene and 1.8% other
phytocannabinoids) were supplied by GW Phar-
maceuticals Ltd (Cambridge, UK). The extracts
(9-THC 0.75 mg/kg + CBD 0.75 mg/kg) were dis-
solved in 5% ethanol, 5% Tween, and 90% saline, and
this combination was administered intraperitoneally
(i.p.) in a single injection in a volume of 10 mL/kg
body weight. The human equivalent dose (HED) cal-
culated with the formula for dose translation based on
body surface area [15] corresponds to 0.04 mg/kg for
each cannabinoid, which is equivalent to the adminis-
tration of a single Sativex® oromucosal spray (2.8 mg
9-THC + 2.8 mg CBD) in a human being weighing
70 kg. At this dose, the compound lacks psychoac-
tivity. Groups of animals were treated once a day for
5 weeks with the extracts or with vehicle alone. The
number of animals included in each group was as
follows: WT 12 months treated with cannabinoids,
n = 9; vehicle alone, n = 8; APP/PS1 12 months with
cannabinoids, n = 11; APP/PS1 12 months treated
with vehicle alone, n = 10; WT aged 3 months treated
with cannabinoids, n = 8; treated with vehicle alone,
n = 7. After a 10-day washing period, animals were
subjected to behavioral evaluation.
Cognitive evaluation and sample collection
Memory performance was evaluated with the two-
object recognition test. On day 1, mice were placed
for 9 min in a V-maze, in which two identical objects
were situated at the ends of the arms; the time that
the mice spent exploring each object was recorded.
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Then, 24 h after the training session, animals were
placed again for 9 min in the V-maze, with one of
the two familiar objects replaced by a novel object.
The time that the animals spent exploring the two
objects was recorded and an object recognition index
(RI) was calculated, as the difference between the
time spent exploring the novel object (TN) and the
familiar object (TF) divided by the total time spent
exploring the two objects [RI = (TN-TF)/(TN+TF)].
At the end of the behavioral testing, the animals
were killed and their brains rapidly removed from
the skull and processed for study. One hemisphere
was dissected on ice, immediately frozen, and stored
at –80◦C until use. The other hemisphere was fixed
in 4% paraformaldehyde and processed for immuno-
histochemistry.
Aβ immunohistochemistry
Fixed tissue samples were embedded in paraf-
fin, and coronal sections, 4 mm thick, were cut
with a microtome. Consecutive de-waxed sections
were incubated with 98% formic acid (3 min) and
then treated with citrate buffer (20 min) to enhance
antigenicity. Then endogenous peroxidases were
blocked by incubation in 10% methanol-1% H2O2
solution (15 min). Sections were blocked with 3%
normal horse serum solution and then incubated at
4◦C overnight with the primary antibody against
total A (clone 6F/3D 1 : 50, Dako, Glostrup, Den-
mark), A40 (1 : 100, Merck Millipore, Billerica,
MA, USA) or A42 (1 : 50, Merck Millipore). Sec-
tions were subsequently rinsed and incubated with
biotinylated secondary antibodies (Dako). Peroxi-
dase reaction was visualized with diaminobenzidine
and H2O2. Sections were slightly counterstained with
hematoxylin. After staining, the sections were dehy-
drated and cover-slipped for observation under a
Nikon Eclipse E800 microscope (Nikon Imaging
Inc., Tokyo, Japan). The cortical total A burden
was calculated as the percentage of the area of amy-
loid deposition in plaques with respect to the total
cortical area (0.6 mm2) in 9 pictures taken from 3
different sections (–0.1 mm, –1.5 mm, and –2.0 mm
from bregma) of the each animal brain (3 pictures
per section corresponding to cingular/retrospenial
and motor cortex, somatosensory cortex, and pir-
iform/entorhinal cortex). The areas selected were
the main regions of the cerebral cortex in which
A is deposited in APP/PS1 mice. In addition,
two sections of the hippocampus of each animal
(–1.5 mm and –2.0 mm from bregma) were used for
quantification of A burden in the hippocampus, cal-
culated as the percentage of the amyloid deposition
in plaques with respect to the total hippocampal area
in each section. The percentage of A42 contents in
each plaque was calculated by comparing the spe-
cific A42 staining with respect to total A42 + A40
staining in at least 25 cortical plaques per animal
in consecutive sections. A researcher who did not
know the treatment received in each group performed
the quantifications. A quantification was calculated
using the Analysis tool of the Adobe® Photoshop®
CS4 software (Adobe Systems Inc., San Jose, CA,
USA). All the APP/PS1-treated animals were
analyzed.
Aβ soluble quantiﬁcation: enzyme-linked
immunosorbent assay (ELISA)
Fresh-frozen mouse brain cortex was homoge-
nized in 4 volumes (wt:vol) of TBS extraction
buffer (140 mM NaCl, 3 mM KCl, 25 mM Tris (pH
7.4), 5 mM EDTA, and protease inhibitor cocktail
(Roche Molecular Systems, Pleasanton, CA, USA).
Homogenate was spun at 100,000 g for 1 h, and the
supernatant was saved as the soluble fraction for A
quantification. A40 and A42 Human ELISA kits
(InvitrogenTM Corporation, Camarillo, CA, USA)
were used to quantify the levels of A40 and A42
peptides in the brain soluble fractions. Quantitative
determination was carried out according to the man-
ufacturer’s instructions. A40 and A42 levels were
normalized to the total amount of protein from each
individual sample (BCA method, Thermo Fisher Sci-
entific, Wilmington, DE, USA). All treated animals
were analyzed but only APP/PS1 mice were used
for quantification because, as expected, no specific
immunolabeling was observed in any WT mice.
Double-labeling immunoﬂuorescence
De-waxed sections were incubated with 98%
formic acid (3 min) for A immunofluorescence and
then treated with citrate buffer (20 min) to enhance
antigenicity. Sections were stained with a saturated
solution of Sudan black B for 30 min (Merck Milli-
pore) to block lipofuscin autofluorescence, rinsed in
70% ethanol and washed in distilled water. After a
blockade with 10% fetal bovine serum (90 min), the
sections were incubated at 4◦C overnight with com-
binations of primary antibodies against A (clone
6F/3D 1 : 50, Dako), glial fibrillary acidic protein
(GFAP; 1 : 250, Dako) and IBA1 (1 : 250, Wako,
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Richmond, VA, USA). After washing, the sections
were incubated with Alexa488 and Alexa546 fluores-
cence secondary antibodies against the corresponding
host species (1 : 400, Molecular Probes, Eugene, OR,
USA). The sections were washed and mounted in
Immuno-Fluore Mounting medium (ICN Biomedi-
cals, Solon, OH, USA), sealed, dried overnight and
examined with a Nikon Eclipse E800 microscope.
The specific GFAP and IBA1 immunostaining den-
sity was calculated in reference to the A plaque area
in 5 representative pictures taken from the cortex of
each animal using the Adobe® Photoshop® CS4 soft-
ware. All the APP/PS1-treated animals were used
for quantifications.
Gel electrophoresis and western blotting
Frozen samples of the somatosensory cortex were
homogenized in RIPA lysis buffer (50 mM Tris/HCl
buffer, pH 7.4 containing 2 mM EDTA, 0.2% Non-
idet P-40, 1 mM PMSF, protease, and phosphatase
inhibitor cocktails, Roche Molecular Systems, USA).
The homogenates were centrifuged for 15 min at
13,000 rpm. Protein concentration was determined
with the BCA method (Thermo Scientific). Equal
amounts of protein (20g) for each sample were
loaded and separated by electrophoresis on sodium
dodecyl sulfate polyacrylamide gel electrophore-
sis (SDS-PAGE) (10%) gels and transferred onto
nitrocellulose membranes (Amersham, Freiburg,
Germany). Non-specific bindings were blocked by
incubation in 3% albumin in PBS containing 0.2%
Tween for 1 h at room temperature. After washing,
membranes were incubated overnight at 4◦C with
the antibodies against thioredoxin 2 (Txn2, 13 kDa,
rabbit, 1 : 1,000, Proteintech, Chicago, IL, USA),
wingless-related integration site 16 (Wnt16, 37 kDa,
rabbit, 1 : 5,000, GeneTex, Irvine, CA, USA), synap-
tosome associated protein 25 kDa (SNAP25, 25 kDa,
mouse, 1 : 1,000, Abcam, Cambridge, UK), post-
synaptic density protein 95 kDa (PSD-95, 95 kDa,
rabbit, 1 : 1,000; Merck Millipore), synaptotagmin
(47 kDa, mouse, 1 : 1,000; Abcam), glutamate recep-
tor 2/3 (GluR2/3, 110 kDa, rabbit, Merck Millipore),
and gamma-aminobutyric acid receptor A subunit
α1 (GABA-A Rα1, 51 kDa, rabbit, Santa Cruz
Biotechnology, Dallas, TX, USA). Protein loading
was monitored using an antibody against -tubulin
(50 kDa, 1 : 10,000, Abcam). Membranes were then
incubated for 1 h in the appropriate HRP-conjugated
secondary antibodies (1 : 2,000, Dako), and immuno-
complexes were revealed by chemiluminescence
reagent (ECL, Amersham). Densitometric quantifi-
cation was carried out with TotalLab v2.01 software
(Pharmacia, Sweden). Bands were normalized to
-tubulin. Six animals per group were analyzed.
Statistical analysis
Statistical analysis was performed with the SPSS®
Statistics v21.0 software (IBM, New York, NY,
USA). The normality of the data was assessed with
the Shapiro-Wilk test, and parametric statistical tests
were used for the analysis of all the data in the
study. Memory data were analyzed with two-way
ANOVA by group (depending on age and genotype)
and treatment, followed by Tukey’s post hoc. Protein
quantifications with western blotting were analyzed
using two-way ANOVA with genotype and treatment
as between factors. A and glia quantifications were
analyzed with Student’s t-test. In all the experiments,
the significance level was set at p < 0.05.
RESULTS
Natural cannabinoids reduce memory deﬁcits in
AβPP/PS1 mice at advanced stages of AD-like
pathology but have no beneﬁcial effects in aged
WT mice
Daily administration of 9-THC and CBD
(0.75 mg/kg each botanical extract i.p.) for 5
weeks at advanced stages of the symptomatic
phase (12 months) blunted the memory impair-
ment observed in vehicle-treated APP/PS1 mice,
as revealed by the two-object recognition test
(Fig. 1). Two-way ANOVA revealed a significant
group (F(2,39) = 7.579, p < 0.01) and treatment effect
(F(1,39) = 4.840, p < 0.05) and interaction between the
two factors (F(2,39) = 6.810, p < 0.01). Subsequent
Tukey’s post hoc tests revealed that vehicle-treated
WT mice aged 12 months (p < 0.05) and vehicle-
treated APP/PS1 mice aged 12 months (p < 0.001)
exhibited memory impairment when compared to
corresponding non-aged control mice. Interestingly,
9-THC + CBD significantly increased the recog-
nition index of 12-month-old APP/PS1 mice when
compared to vehicle-treated littermates (p < 0.001).
However, the treatment was not effective in reducing
the memory impairment exhibited by 12-month-old
WT mice. Treated mice were also tested in the active
avoidance test, which is a more complex task and
involves both memory and learning processes. How-
ever, aged WT mice evidenced difficulties to perform
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Fig. 1. Memory performance of animals in the two-object recogni-
tion test. WT and APP/PS1 mice aged 12 months at the beginning
of the study exhibit a significant reduction in the recognition index
when compared with non-aged control mice (3 months old WT
mice). Daily administration of 9-THC + CBD (0.75 mg/kg each
botanical extract i.p.) for 5 weeks blunts memory impairment of
AβPP/PS1 mice at advanced stages (12 months). However, it is
not effective in reducing memory impairment in 12-month-old
WT littermates. Data are expressed as the mean values ± SEM;
∗∗∗p < 0.001 treatment effect; #p < 0.05, ###p < 0.001 compared to
vehicle-treated non-aged control mice.
this test, thus invalidating the possibility to dis-
tinguish cognitive performance between genotypes
(data not shown).
The combination of Δ9-THC and CBD does not
alter Aβ processing in AβPP/PS1 mice at
advanced stages of the disease
Chronic treatment with the combination of 9-
THC + CBD did not significantly modify total
A burden in the neocortex and hippocampus of
APP/PS1 mice (Fig. 2A, B). In contrast to what
was previously observed at early stages of AD-like
pathology in APP/PS1 mice [11], 9-THC + CBD
was not able to reduce the level of soluble A42 and
A40 when administered at advanced stages of the
disease (Fig. 2E). In the same line, natural cannabi-
noids failed to induce a change in the composition
of A plaques similar to that observed when treat-
ment was applied at early stages [13]. Despite an
upward trend (p = 0.119), the percentage of A42 in
each plaque was not significantly increased in treated
mice (Fig. 2C, D). None of the assessed A forms
was detectable in WT littermates (data not shown).
Gliosis related to Aβ deposition was not modiﬁed
in AβPP/PS1 mice treated at advanced stages
In contrast to our previous observations show-
ing reduced astroglial and microglial reactivity in
the vicinity of A deposits in APP/PS1 mice
treated with 9-THC + CBD during the early symp-
tomatic stages [13], the present results show that the
same combination of natural cannabinoids was not
able to reduce glial reactivity in APP/PS1 mice
when administered at advanced stages of the disease
(Fig. 3).
Δ9-THC and CBD combination modiﬁes the
levels of several synaptic and neurotransmission
markers
In order to evaluate the possible molecular mecha-
nisms underlying the beneficial effects of 9-THC +
CBD on APP/PS1 mice at advanced stages, we ana-
lyzed, using western blotting, selected proteins linked
to redox metabolism, and synapses and neurotrans-
mission in cortical homogenates (Fig. 4). First, we
evaluated the levels of the redox protein Txn2 and the
signaling protein Wnt16. However, two-way ANOVA
revealed no significant effect of treatment indepen-
dently of genotype, and no interaction between the
two factors on the levels of Txn2 or Wnt16 in
cortical homogenates of APP/PS1-mice treated at
advanced stages. Next, we evaluated the levels of cer-
tain proteins involved in the regulation of synaptic
plasticity and function, including SNAP25, PSD-
95 and synaptotagmin. 9-THC + CBD induced an
effect on the levels of SNAP25 (Genotype effect:
F(1,18) = 0.61, N.S.; Treatment effect: F(1,18) = 7.07,
p < 0.05; Interaction: F(1,18) = 3.08, N.S.). Thus,
chronic treatment reduced the amounts of SNAP25
protein in APP/PS1 mice, which were elevated in
comparison to WT littermates, when compared to
APP/PS1 mice treated with vehicle alone (p < 0.05).
In contrast, cannabinoids did not reduce the ele-
vated levels of PSD-95 observed in APP/PS1 mice
(Genotype effect: F(1,19) = 6.03, p < 0.05; Treatment
effect: F(1,19) = 0.01, N.S.; Interaction: F(1,19) = 0.29,
N.S.). When compared to WT mice, the increase
in PSD-95 only reached statistical significance in
9-THC + CBD-treated APP/PS1 mice (p < 0.05),
although a clear tendency was also observed in
vehicle-treated APP/PS1 mice. Two-way ANOVA
revealed no significant effect of treatment or geno-
type, nor interaction between the two factors, at the
level of synaptotagmin in treated mice. Finally, we
evaluated the protein levels of the metabotropic glu-
tamate receptor 2/3 (GluR2/3) and the ionotropic
GABA-A receptor α1. Two-way ANOVA revealed
that chronic treatment significantly modulated
both GluR2/3 (Genotype effect: F(1,19) = 16.492,
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Fig. 2. A) Representative images of the A immunoreactivity in somatosensory cortex (top) and hippocampus (bottom) in vehicle- (left)
and 9-THC + CBD-treated (right) APP/PS1 mice. Scale bars represent 200m (cortex) or 500m (hippocampus). B) Total A burden
quantification reveals no treatment effect in cortex and hippocampus in aged APP/PS1 mice. C) Representative images of the A40 (top)
and A42 (bottom) immunoreactivity in consecutive cortical sections of vehicle- (left) and 9-THC + CBD-treated (right) APP/PS1 mice
aged 12 months at the beginning of the study. Scale bar represents 50m. D) Quantification of the percentage of A42 contents with respect
to total A42 + A40 levels in each plaque reveals no significant effect in spite of a tendency toward increase in 9-THC + CBD-treated
mice. E) The combination of 9-THC + CBD does not modify soluble A40 and A42 levels in cortical homogenates from APP/PS1 mice
treated at advanced stages of the disease. Counts are expressed as the mean values ± SEM.
p < 0.001; Treatment effect: F(1,19) = 0.09, N.S.;
Interaction: F(1,19) = 7.09, p < 0.05) and GABA-A
Rα1 receptors (Genotype effect: F(1,19) = 0.23, N.S.;
Treatment effect: F(1,19) = 1.93, N.S.; Interaction:
F(1,19) = 8.93, p < 0.01). Thus, subsequent post hoc
tests showed that 9-THC + CBD significantly
E. Aso et al. / Cannabinoid Efﬁcacy in Advanced Dementia 909
Fig. 3. A) Representative images of double GFAP (red, upper panels) and IBA1 (red, lower panels) and A (green) immunoreactivity in
sections of the neocortex of APP/PS1 mice chronically treated with natural cannabinoids at the age of 12 months. Scale bars represent
50m. B) Quantification of the GFAP and IBA1 staining around A plaques reveals no significant effect of the treatment on astrocytes and
microglia in APP/PS1 mice when administered at advanced stages of the disease. Data are expressed as the mean values ± SEM.
reduced the levels of GluR2/3 in APP/PS1 mice
compared to vehicle-treated (p < 0.05) and WT lit-
termates (p < 0.01), and increased the GABA-A Rα1
levels with respect to vehicle-treated APP/PS1 mice
(p < 0.05), which exhibited reduced levels compared
to WT animals (p < 0.05).
DISCUSSION
During the last decade, targeting of the endogenous
cannabinoid system has emerged as a promising ther-
apy against Alzheimer-type dementia because endo-
cannabinoid signaling modulates some pathological
processes linked to neurodegenerative processes,
including protein misfolding, neuroinflammation,
excitotoxicity, mitochondrial dysfunction, and oxida-
tive stress [3–6]. However, most evidence is based on
observations in experimental models at early stages of
the disease. The present study analyzes the efficacy of
a cannabis-based medicine, composed essentially of
9-THC and CBD, at advanced stages of Alzheimer-
type dementia in APP/PS1 transgenic mice.
Collaterally, we evaluated the therapeutic profile of
the9-THC and CBD combination in WT littermates
used as a model of aging. We chose the combination
of these two natural cannabinoids because, although
previous findings revealed that both 9-THC and
CBD given alone resulted in beneficial cognitive
effects in APP/PS1 mice [13, 16, 17], the combi-
nation of 9-THC and CBD was more effective than
either cannabinoid alone in these transgenic animals
when administered at early stages [13].
The present results show that treatment with 9-
THC and CBD at non-psychoactive doses reduces
memory impairment occurring in APP/PS1 mice at
12 months of age when the progression of the dis-
ease is at an advanced stage. These findings might
appear to contradict the evidence about the cognitive
impairment induced by 9-THC exposure in healthy
mice [18]. However, the doses employed revealing
memory impairments in mice [18] are much higher
than the dose used here showing a neuroprotective
effect. Second, the brain context of young healthy
mice exposed to high doses of 9-THC is different
from that of aged AD mice, since molecular reor-
ganization of the endogenous cannabinoid system
and altered neuronal signaling are found in AD [19].
These differences may explain different 9-THC-
linked effects in these two groups of mice. Finally, the
combination of natural cannabinoids administered in
the present study is composed of 9-THC in a simi-
lar proportion to CBD, which is known to antagonize
9-THC-induced deficits in memory [20].
The 9-THC- and CBD-enriched extract combi-
nation administered at advanced stages of the disease
does not modify A burden or the glial reactivity
associated with aberrant A deposition in APP/PS1
mice, in contrast to the effect when administered at
early stages of the disease [13]. Thus, these findings
suggest that natural cannabinoids modulate mecha-
nisms other than A processing and glial reactions
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Fig. 4. Western blot quantification of proteins in somatosensory cortex homogenates in WT and APP/PS1-treated mice with cannabinoids
or with vehicle alone: thioredoxin 2 (Txn2), wingless-related integration site (Wnt16), synaptosome associated protein-25 (SNAP25),
post-synaptic density protein-95 (PSD-95), synaptotagmin, glutamate receptor 2/3 (GluR2/3) and gamma-aminobutyric acid receptor A
α1 (GABA-A Rα1). A) Representative immunoblots for Txn2, Wnt16, SNAP25, PSD-95, synaptotagmin, GluR2/3, GABA-A Rα1, and
corresponding -tubulin loading control indicating the molecular weight of proteins. B) Optical density quantification of each immunoblot
with respect to WT-vehicle group which is considered as control. No significant change in the total amount of Txn2 or Wnt16 is observed in any
group. However, the 9-THC + CBD combination normalizes SNAP25 levels but fails to reduce levels of PSD-95 or to modify synaptotagmin
protein levels. 9-THC + CBD modifies the expression of certain neurotransmission-related molecules. Thus, APP/PS1-treated mice exhibit
significantly lower levels of GluR2/3 and increased levels of GABA-A Rα1 protein when compared with vehicle-treated transgenic mice.
Densitometric quantifications are expressed as mean values ± SEM. ∗p < 0.05 treatment effect. #p < 0.05, ##p < 0.01, genotype effect.
which contribute to cognitive improvement revealed
in APP/PS1 mice treated at advanced stages of
the disease. We may speculate that the mechanisms
involved in this cannabinoid-induced beneficial effect
on memory performance are specific for neurode-
generative dementia since the 9-THC and CBD
combination is ineffective at reducing mild cognitive
impairment in old WT littermates used as a model of
behavior deterioration linked to old age.
Among the potential molecular mechanisms
involved in the beneficial effects induced by the
9-THC and CBD combination in APP/PS1 mice
treated at advanced stages of the disease, we focused
our attention on evaluating three groups of proteins:
(i) Txn2 and Wnt16, two proteins that play a role in
the 9-THC + CBD-induced effects on APP/PS1
mice when treated at early stages of the disease [13],
(ii) SNAP25, which is associated with synaptosome
and contributes to the formation of the exocytotic
fusion complexes in neurons, PSD-95, located in
the post-synaptic density of neurons and involved in
receptors clustering, modulation of ion channels and
associated signaling proteins, and synaptotagmin, a
presynaptic Ca2+ sensor involved in the regulation of
the traffic of synaptic vesicles and neurotransmitter
release, as markers of synaptic plasticity and function,
and (iii) GluR2/3 and GABA-A Rα1, both involved in
the regulation of neurotransmission in cortical brain
areas. The selection of these markers was based on
previous evidence about the role of cannabinoids
in modulating synaptic signaling and function [21,
22]. In contrast to what happened when 9-THC
and CBD were administered at early stages [13],
the combination of these natural cannabinoids fails
to modify the levels of the redox protein Txn2 and
the signaling molecule Wnt16 in the somatosensory
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cortex of aged APP/PS1 mice. However, the com-
bination of 9-THC and CBD induces some changes
in markers of synaptic function, which might be
related to the cognitive improvement observed in
APP/PS1 mice treated during advanced stages of
the disease. Thus, chronic treatment normalized the
levels of the pre-synaptic SNAP25, but not the
post-synaptic PSD-95 protein, in APP/PS1 mice.
Increased levels of synaptic proteins such as SNAP25
were previously associated with aberrant neuritic
sprouting in brain areas affected by A synthesis
and deposition in AD [23], suggesting that 9-THC
and CBD might contribute to reducing this patho-
logical process. More importantly, APP/PS1 mice
treated with 9-THC and CBD at advanced stages
exhibit a reduction in GluR2/3 expression levels
accompanied by an increase in the expression of
GABA-A Rα1. These results suggest that natural
cannabinoids alter the imbalance of excitatory ver-
sus inhibitory neural activity in the somatosensory
cortex of aged APP/PS1 mice [24, 25]. In fact, A
has been demonstrated to inhibit long-term plastic-
ity processes associated with learning and memory
through suppression of CB1-dependent GABAergic
synaptic disinhibition [26]. Moreover, CB1 receptor
activity in GABAergic neurons protects against age-
dependent cognitive decline [27]. Therefore, it may
be speculated that the combination of 9-THC and
CBD facilitates inhibitory GABAergic activity in the
somatosensory cortex by mitigating the deleterious
effect of A on GABAergic function, and subse-
quently on cognitive performance, via activation of
CB1 receptors. 9-THC is also known to depress
glutamate synaptic transmission via CB1 receptor
activation, affecting glutamate release, inhibiting
receptors and transporters function, reducing enzyme
activity, and disrupting glutamate synaptic plasticity
after prolonged exposure [28]. Thus, the reduc-
tion of GluR2/3 expression observed on treated
mice might be the result of such depressed gluta-
matergic activity induced by chronic stimulation of
CB1 receptor. These modifications could contribute
to counteract the alterations in neural excitabil-
ity observed in APP/PS1 mice [24, 25] and in
turn to improve cognitive performance. However,
further experimental evidence will be needed to
confirm the specific role of CB1 receptors in such
effects.
In light of these observations, and of the fact that
Sativex® is devoid of psychoactivity and is well-
tolerated at the dose proposed in our studies [29],
potential translation to human beings might offer
a safe and effective therapeutic agent in advanced
Alzheimer-type dementia.
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